เอกสารการประชุมวิชาการและเสนอผลงานวิจัย มหาวิทยาลัยทักษิณ ครั้งที่ 19 2552 - page 899

7
„µ¦ž¦³»¤ª·µ„µ¦Â¨³Áœ°Ÿ¨Šµœª·‹´¥¤®µª· š¥µ¨´¥š´„¬·– ‡¦´ÊŠš¸É 19 ž¦³‹Îµže 2552
—´Š‹³Á®ÈœÅ—oªnµ¦¼žÂ °ŠÃž¦˜¸œÄœµ¦„´—®¥µ‹³¤¸ž¦·¤µ–Þ¦˜¸œš¸É‡n°œ oµŠ¼Š ‹¹ŠšÎµÄ®o¤¸ž¦· ¤µ–
™Ãž¦˜¸œš¸É¤µ„„ªnµ Á¤ºÉ°Áž¦¸¥Áš¸¥¦¼žÂ„µ¦Â¥„°°„ °ŠÃž¦˜¸œÄœ„µ¦Â¥„—oª¥¦³ ATPS ¡ªnµ ¦¼žÂ
Þ¦˜¸œÄœ´Êœ PEG ‹³¤¸ž¦·¤µ–Þ¦˜¸œš¸É¨—¨ŠšÎµÄ®o¤¸Â™Ãž¦˜¸œÁ¡¸ ¥Š 3 œµ—‡º° 44.38 19.72 ¨³ 9.64 kDa Á¤ºÉ°
Áš¸¥„´´ÊœÁ„¨º °š¸É¥´Š‡Š¤¸Â™Ãž¦˜¸œš¸É¤µ„„ªn µ ÁœºÉ°Š¤µ‹µ„Þ¦˜¸œš¸É¤¸‡»–¤´˜·Áž}œ hydrophobic protein Á¤ºÉ °
¨³¨µ¥°¥¼nĜ °ŠŸ¤¦³®ªnµŠÁ„¨º° (Tripotassium citrate) ¨³¡°¨· Á¤°¦r (PEG) Á¤ºÉ°™¹Š‹»—¤—»¨‹³Á„·—„µ¦Â¥„´Êœ
ץÞ¦˜¸ œš¸É¤¸‡»–¤´˜·Å¤n¤¸´Êª„È‹³™¼„¨³¨µ¥Äœ´Êœ PEG ŗo—¸ Ž¹É ŠÁž}œ„µ¦„ε‹´—Þ¦˜¸œnªœ°ºÉœš¸ÉŤn˜o°Š„µ¦°°„
šÎ µÄ®o¤¸‡ªµ¤¦· »š›·ÍÁ¡·É¤ ¹Êœ—´Š˜µ¦µŠš¸É 4
˜µ¦µŠš¸É 4 —Šž¦· ¤µ–Á°œÅŽ¤rŨÁžž¦· ¤µ–Þ¦˜¸œ ¨³‡ªµ¤¦· »š›·Í°Šµ¦„´—´ —š¸É˜nµŠ„´œ
Treatment Total Activity
(Units)
Total protein
(mg) Specific activity Fold purify
Crude extracted 25.39 1605.57 1.58 1.00
Salt phase 13.91 1051.44 1.32 0.84
PEG phase 11.19 169.35 6.61 4.18
„µ¦Â¥„Á°œÅŽ¤rŨÁž—oª¥Áš‡œ·‡ gelfiltration chromatography
‹µ„„µ¦Â¥„Á°œÅŽ¤rŨÁžš´ÊŠÄœ´ÊœÁ„¨º° ¨³´Êœ PEG š¸Éŗo‹µ„„µ¦Â¥„ŨÁž—oª¥¦³ ATPS ¡ªnµ‹³
¤¸Ã‡¦¤µÃšÂ„¦¤—´Š£µ¡š¸É 3
£µ¡š¸É 3 —ŠÃ‡¦¤µÃšÂ„¦¤ °Š„µ¦Â¥„Á°œÅŽ¤rŨÁžš´ÊŠÄœ´ÊœÁ„¨º° ¨³´Êœ PEG —oª¥ Sephadex-G
100 ‡°¨´¤œr
‹µ„Ǧ¤µÃšÂ„¦¤ °Š Sephadex-G 100 ‡ªµ¤¥µª 60 Ž¤. š¸É¡¸ Á° 8 ‹³¡ªnµÁ¤ºÉ°œÎ µ´ÊœÁ„¨º°¤µŸn µœ
‡°¨´¤œr‹³¡Â°‡˜· ª·˜¸Ê°ŠÁ°œÅŽ¤rŨÁž¡¸‡š¸É 2 Ášnµ„´œ 0.121±0.007 units/ml ¨³Á¤ºÉ°œÎµ´Êœ PEG ¤µŸn µœ‡°¨´¤œr
‹³¡Â°‡˜·ª·˜¸Ê°ŠÁ°œÅŽ¤rŨÁž¡¸ ‡š¸É 7 Ášnµ„´œ 0.098±0.003 units/ml —ŠÄ®oÁ®Èœªn µÄœ„µ¦Â¥„Á°œÅŽ¤rŨÁž—o
ª¥¦³ ATPS ĜÁœºÊ°¤³¡¦oµª°µ‹¤¸Á°œÅŽ¤rŨÁž 2 œ· —š¸ÉÁž}œ isozyme „´ œ
1
2 3
4
5
6 1
2
3
4 5 7
8